Ticker LaunchReverse merger · Pending · NRTX
North Immunology, Inc.
Reverse merger with Aethlon Medical, Inc. (AEMD)
North Immunology, Inc. agreed to merge into Aethlon Medical, Inc. (AEMD), a Nasdaq medical device company (Hemopurifier) with legacy assets, in a reverse merger that takes the private company public. The deal was announced on Sep 17, 2026. The combined company is expected to trade as North Immunology, Inc. (NRTX) on Nasdaq.
North Immunology, Inc. is a privately held biotech developing NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody for atopic dermatitis and other immune-mediated diseases, with Phase 1a expected to begin in Q1 2027.
- Status
- Pending
- Private company
- North Immunology, Inc.
- Public company
- Aethlon Medical, Inc. (AEMD)
- Public company business before
- Nasdaq medical device company (Hemopurifier) with legacy assets
- Announced
- Sep 17, 2026
- Combined company
- North Immunology, Inc. (NRTX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Contingent value rights (CVR)
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement 8-K Sep 17, 2026
- Announcement press release Sep 17, 2026
- 8-K (items 5.02,5.07,9.01) Oct 1, 2026
- All filings on EDGAR CIK 882291
Other pending reverse mergers
- Santersus AGinto Xenetic Biosciences, Inc. · Sep 16, 2026
- Ambros Therapeutics, Inc.into Werewolf Therapeutics, Inc. · Aug 21, 2026
- Slate Medicines, Inc.into Fulcrum Therapeutics, Inc. · Aug 17, 2026
- Redx Pharma Limitedinto Skye Bioscience, Inc. · Aug 14, 2026
- Caldera Therapeutics, Inc.into Synlogic, Inc. · Jul 29, 2026
- GH Power Inc.into Matinas BioPharma Holdings, Inc. · Jul 13, 2026